-$0.80 EPS Expected for NewLink Genetics Corporation (NLNK) This Quarter
Equities research analysts forecast that NewLink Genetics Corporation (NASDAQ:NLNK) will announce earnings per share (EPS) of ($0.80) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for NewLink Genetics Corporation’s earnings. The lowest EPS estimate is ($0.87) and the highest is ($0.75). NewLink Genetics Corporation posted earnings of ($0.54) per share in the same quarter last year, which would suggest a negative year over year growth rate of 48.1%. The firm is expected to report its next earnings report on Tuesday, November 7th.
According to Zacks, analysts expect that NewLink Genetics Corporation will report full-year earnings of ($2.79) per share for the current year, with EPS estimates ranging from ($3.05) to ($2.64). For the next financial year, analysts forecast that the firm will report earnings of ($2.44) per share, with EPS estimates ranging from ($3.29) to ($1.71). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover NewLink Genetics Corporation.
NewLink Genetics Corporation (NASDAQ:NLNK) last announced its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.21. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. The company had revenue of $10.37 million for the quarter, compared to analyst estimates of $2.65 million.
Several brokerages recently issued reports on NLNK. Bank of America Corporation began coverage on shares of NewLink Genetics Corporation in a report on Friday, October 13th. They set a “buy” rating and a $22.00 price target on the stock. ValuEngine lowered shares of NewLink Genetics Corporation from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 26th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $26.00 price target on shares of NewLink Genetics Corporation in a report on Monday, September 25th. Stifel Nicolaus lifted their price target on shares of NewLink Genetics Corporation from $14.00 to $29.00 and gave the company a “buy” rating in a report on Monday, September 11th. Finally, Robert W. Baird raised shares of NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $8.00 to $22.00 in a report on Friday, September 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $25.83.
In other NewLink Genetics Corporation news, major shareholder Stine Seed Farm, Inc. bought 780,487 shares of the business’s stock in a transaction that occurred on Friday, October 6th. The shares were acquired at an average cost of $10.25 per share, for a total transaction of $7,999,991.75. Following the transaction, the insider now directly owns 7,857,732 shares in the company, valued at $80,541,753. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 13.70% of the stock is owned by company insiders.
A number of large investors have recently bought and sold shares of NLNK. State of Wisconsin Investment Board acquired a new stake in NewLink Genetics Corporation during the 2nd quarter worth approximately $125,000. Trexquant Investment LP boosted its position in NewLink Genetics Corporation by 39.1% during the 2nd quarter. Trexquant Investment LP now owns 18,132 shares of the biotechnology company’s stock worth $133,000 after buying an additional 5,097 shares during the period. Advisor Group Inc. boosted its position in NewLink Genetics Corporation by 3.4% during the 2nd quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after buying an additional 600 shares during the period. The Manufacturers Life Insurance Company boosted its position in NewLink Genetics Corporation by 3.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after buying an additional 556 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new stake in NewLink Genetics Corporation during the 2nd quarter worth approximately $165,000. Institutional investors and hedge funds own 54.77% of the company’s stock.
NewLink Genetics Corporation (NASDAQ NLNK) opened at 10.08 on Monday. The stock’s 50 day moving average is $11.21 and its 200-day moving average is $11.01. The firm’s market capitalization is $296.56 million. NewLink Genetics Corporation has a 12 month low of $5.90 and a 12 month high of $25.17.
About NewLink Genetics Corporation
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.